BR112016018681A2 - implante que compreende fgf-18 - Google Patents

implante que compreende fgf-18

Info

Publication number
BR112016018681A2
BR112016018681A2 BR112016018681A BR112016018681A BR112016018681A2 BR 112016018681 A2 BR112016018681 A2 BR 112016018681A2 BR 112016018681 A BR112016018681 A BR 112016018681A BR 112016018681 A BR112016018681 A BR 112016018681A BR 112016018681 A2 BR112016018681 A2 BR 112016018681A2
Authority
BR
Brazil
Prior art keywords
fgf
implant
cartilage
osteoarthritis
membranes
Prior art date
Application number
BR112016018681A
Other languages
English (en)
Other versions
BR112016018681B1 (pt
Inventor
H Ladel Christoph
Guehring Hans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112016018681A2 publication Critical patent/BR112016018681A2/pt
Publication of BR112016018681B1 publication Critical patent/BR112016018681B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a invenção refere-se ao campo de composições farmacêuticas. mais particularmente, ela é dirigida a sistemas de distribuição de substâncias (ou implante), tais como suportes e membranas, que compreendem um fármaco anabólico, tal como um composto de fator de crescimento de fibroblastos 18 (fgf-18), a métodos de produção de tal sistema de distribuição, bem como seu uso. os implantes de acordo com a invenção são para uso para o tratamento de transtornos de cartilagem, tais como osteoartrite, lesão da cartilagem ou defeitos osteocondrais.
BR112016018681-8A 2014-02-20 2015-02-20 sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura BR112016018681B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000598.4 2014-02-20
EP14000598 2014-02-20
PCT/EP2015/053645 WO2015124739A1 (en) 2014-02-20 2015-02-20 Implant comprising fgf-18

Publications (2)

Publication Number Publication Date
BR112016018681A2 true BR112016018681A2 (pt) 2017-10-17
BR112016018681B1 BR112016018681B1 (pt) 2021-01-05

Family

ID=50151086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018681-8A BR112016018681B1 (pt) 2014-02-20 2015-02-20 sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura

Country Status (24)

Country Link
US (1) US10086112B2 (pt)
EP (1) EP3107592B1 (pt)
JP (1) JP6510547B2 (pt)
KR (1) KR102421950B1 (pt)
CN (1) CN106232154A (pt)
AR (1) AR099556A1 (pt)
AU (1) AU2015220785B2 (pt)
BR (1) BR112016018681B1 (pt)
CA (1) CA2938796C (pt)
DK (1) DK3107592T3 (pt)
ES (1) ES2698117T3 (pt)
HR (1) HRP20181573T1 (pt)
IL (1) IL247106B (pt)
LT (1) LT3107592T (pt)
MX (1) MX368946B (pt)
NZ (1) NZ723177A (pt)
PL (1) PL3107592T3 (pt)
PT (1) PT3107592T (pt)
RS (1) RS58138B1 (pt)
RU (1) RU2700414C2 (pt)
SG (1) SG11201606697YA (pt)
SI (1) SI3107592T1 (pt)
WO (1) WO2015124739A1 (pt)
ZA (1) ZA201605667B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2959509B1 (en) 2013-02-14 2018-05-23 Nanopareil, Llc Electrospun hybrid nanofibre felt, method for making the same, and method for purifying biomolecules
US9889179B2 (en) 2014-02-20 2018-02-13 Merck Patent Gmbh FGF-18 compound dosing regimen
CN117187255B (zh) * 2023-11-07 2024-01-30 北京大学第三医院（北京大学第三临床医学院） 编码FGF18或rhFGF18的mRNA及其在骨关节炎治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896825B1 (en) * 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
KR100380119B1 (ko) * 2001-04-19 2003-04-11 한국항공우주연구원 이원화된 통신속도 적응형 베이스 밴드 스위칭 위상시프트 키잉 장치
EP1273365A1 (fr) * 2001-07-06 2003-01-08 Recherche Et Developpement Du Groupe Cockerill Sambre Outils rotatifs pour le perçage en ligne de produits profiles
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
US8852240B2 (en) * 2004-10-25 2014-10-07 Kieran Murphy, Llc Methods and compositions for fostering and preserving bone growth
CA2592261C (en) * 2004-12-10 2015-11-24 Zymogenetics Inc. Fgf18 production in prokaryotic hosts
SI2054050T1 (sl) * 2006-08-25 2012-12-31 Ares Trading S.A. Zdravljenje hrustanäśnih obolenj z fgf-18
EP2403514A4 (en) * 2009-03-05 2012-11-14 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods of treating osteocartilaginous defects
US8431399B2 (en) 2010-03-02 2013-04-30 Taipei Medical University Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro
US10130687B2 (en) * 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
JP5990720B2 (ja) * 2011-02-22 2016-09-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨再生及び／又は軟骨再生に使用するためのナノリザーバー技術
WO2015097236A2 (en) * 2013-12-24 2015-07-02 Ares Trading S.A Fgf-18 formulation in alginate/collagen hydrogels
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
US9889179B2 (en) 2014-02-20 2018-02-13 Merck Patent Gmbh FGF-18 compound dosing regimen

Also Published As

Publication number Publication date
DK3107592T3 (en) 2018-11-12
PT3107592T (pt) 2018-12-03
CA2938796C (en) 2022-08-02
AU2015220785A1 (en) 2016-09-01
LT3107592T (lt) 2018-12-10
US20170056560A1 (en) 2017-03-02
RU2016137291A (ru) 2018-03-21
BR112016018681B1 (pt) 2021-01-05
ES2698117T3 (es) 2019-01-31
MX2016010874A (es) 2016-11-17
JP2017507145A (ja) 2017-03-16
AU2015220785B2 (en) 2018-07-19
SI3107592T1 (sl) 2018-11-30
MX368946B (es) 2019-10-22
AR099556A1 (es) 2016-08-03
EP3107592A1 (en) 2016-12-28
RU2016137291A3 (pt) 2018-08-28
KR20160124806A (ko) 2016-10-28
RS58138B1 (sr) 2019-02-28
SG11201606697YA (en) 2016-09-29
JP6510547B2 (ja) 2019-05-08
HRP20181573T1 (hr) 2018-11-30
CA2938796A1 (en) 2015-08-27
RU2700414C2 (ru) 2019-09-17
CN106232154A (zh) 2016-12-14
PL3107592T3 (pl) 2019-02-28
US10086112B2 (en) 2018-10-02
ZA201605667B (en) 2018-12-19
NZ723177A (en) 2021-12-24
IL247106A0 (en) 2016-09-29
KR102421950B1 (ko) 2022-07-18
EP3107592B1 (en) 2018-08-22
WO2015124739A1 (en) 2015-08-27
IL247106B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CL2018001868A1 (es) Análogos del egf(a) con sustituyentes de ácidos grasos.
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EP3731846A4 (en) DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
CL2018001085A1 (es) Derivados de indolin-2-ona
NZ728401A (en) High purity oritavancin and method of producing same
BR112019008239A2 (pt) formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos
BR112017013696A2 (pt) peptídeos e seu uso no tratamento de pele
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2015, OBSERVADAS AS CONDICOES LEGAIS.